MSMesut Seker

Mesut Seker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mesut Seker has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer

    by Mehmet Haluk Yucel, Maral Martin Mildanoglu, Ebru Engin Delipoyraz, Hakan Ozcelik, Erdem Sunger, Sena Fidan, Cihat Terzioglu, Tansel Cakir, Harun Muglu, Burcin Cakan Demirel, et al.

    1. Despite the addition of immune checkpoint inhibitors (ICIs) to platinum-etoposide as first-line therapy, extensive-stage small cell lung cancer (ES-SCLC) remains a highly lethal disease, with a ...

  • Open Access

    A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score

    by Erdem Sünger, Harun Muğlu, Mehmet Haluk Yücel, Ebru Engin Delipoyraz, Maral Martin Mıldanoğlu, Hakan Özçelik, Sena Fidan, Cihat Terzioğlu, Burçin Çakan Demirel, Jamshid Hamdard, et al.

    Objective: To evaluate the Tumor-Immune-Proliferation-Inflammation (TIPI) score as a composite biomarker for predicting pathological complete response (pCR) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with neoadjuvant therapy. Methods: This retrospective single-center study included 75 patients with HER2-positive invasive breast cancer treated with neoadjuvant chemotherapy plus dual anti-HER2 blockade (trastuzumab and pertuzumab). The association between the TIPI score and pCR was assessed using receiver operating characteristic (ROC) analysis and logistic regression. Results: pCR was achieved in 34 patients (45.3%). The optimal TIPI cut-off was 11.41. Patients with high TIPI scores had a higher pCR rate than those with low TIPI scores (56.3% vs. 25.9%, p = 0.016). However, the discriminative performance of the score was modest (AUC 0.598, 95% CI: 0.467–0.730; p = 0.145). In the adjusted analysis, hormone receptor negativity remained the most consistent factor associated with pCR. Conclusions: The TIPI score was developed as a preliminary composite model integrating selected tumor- and host-related biological variables and showed an exploratory association with pCR in this single-center HER2-positive cohort. Given the modest discriminative performance and lack of external validation, these findings should be interpreted cautiously. Further validation in larger independent cohorts is required before the score can be considered for clinical stratification or implementation.

  • Open Access

    Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy

    by Maral Martin Mıldanoğlu, Fatih Kemik, Melisa Eryaşar, Hakan Özçelik, Erdem Sünger, Mehmet Haluk Yücel, Ebru Engin Delipoyraz, Sena Fidan, Harun Muğlu, Burçin Çakan Demirel, et al.

    Introduction: Inflammatory and immune-based prognostic markers such as the Lung Immune Prognostic Index (LIPI) and the Glasgow Prognostic Score (GPS) have gained increasing attention in ES-SCLC, particularly in patients receiving first-line chemoimmunotherapy. However, no prior study has explored a broader, integrated inflammatory framework that evaluates these parameters collectively. Methods: We retrospectively evaluated 166 patients with ES-SCLC treated with first-line platinum–etoposide plus atezolizumab or durvalumab between 2019 and 2025. LIPI could be calculated in 123 patients based on available dNLR and LDH values, while GPS and the Combined Inflammatory Prognostic Score (CIPS) could be assessed in 120 patients with accessible CRP and albumin data. Results: Median PFS and OS were 8.16 and 15.96 months, respectively. In univariate analyses, poor ECOG PS, liver and bone metastases, poor LIPI, poor GPS, and high-risk CIPS were associated with shorter PFS and OS. In multivariate analysis, only LIPI and GPS remained independent predictors of both PFS and OS, while ECOG PS was independently associated with OS. Although CIPS demonstrated clear prognostic separation in univariate analysis, it did not retain independent significance, likely due to sample size limitations and overlap with LIPI and GPS components. Conclusions: LIPI and GPS are strong independent prognostic markers in ES-SCLC receiving chemoimmunotherapy. While CIPS did not demonstrate independent prognostic value in multivariate analysis, its simplicity, balanced two-tier design, and use of routinely available biomarkers highlight its potential clinical utility. To our knowledge, this is the first study to assess a combined inflammatory prognostic model in this population. Prospective multicenter validation is warranted.

  • Open Access

    Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

    by Maral Martin Mildanoglu, Mehmet Haluk Yucel, Ebru Engin Delipoyraz, Erdem Sunger, Hakan Ozcelik, Sena Fidan, Cihat Terzioglu, Harun Muglu, Jamshid Hamdard, Burcin Cakan Demirel, et al.

    Background: Immune checkpoint inhibitors (ICIs) have become the standard first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression. However, the optimal selection between immunotherapy monotherapy and chemo-immunotherapy in patients with a PD-L1 tumor proportion score (TPS) ≥ 50% remains uncertain in routine clinical practice. Methods: We retrospectively reviewed patients with metastatic NSCLC and a PD-L1 TPS ≥ 50% who initiated first-line treatment with pembrolizumab monotherapy or pembrolizumab combined with platinum-based chemotherapy at the Istanbul Medipol University Department of Medical Oncology between July 2017 and December 2024. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated and compared according to PD-L1 expression levels and treatment strategy. Prognostic factors associated with survival outcomes were also explored. Results: A total of 65 patients were included, of whom 36 received pembrolizumab plus chemotherapy and 29 received pembrolizumab monotherapy. The estimated median PFS and OS for the entire cohort were 24.2 months (95% CI, 6.5–33.0) and 34.6 months (95% CI, 6.5–62.7), respectively. Patients with very high PD-L1 expression (TPS ≥ 90%) experienced significantly longer survival outcomes compared with those with a TPS of 50–89%, and a PD-L1 TPS ≥ 90% remained an independent prognostic factor for OS. When treatment strategies were compared across the entire cohort, no statistically significant differences in PFS or OS were observed between immunotherapy monotherapy and chemo-immunotherapy. Hypertension was identified as an independent negative prognostic factor for PFS. In patients with a PD-L1 TPS ≥ 90%, survival outcomes numerically favored pembrolizumab monotherapy, although this difference did not reach statistical significance. Conclusions: In this real-world cohort of patients with PD-L1 high metastatic NSCLC, PD-L1 expression, particularly very high TPS levels, was strongly associated with survival outcomes. While no survival differences were observed between treatment strategies in the overall population, pembrolizumab monotherapy may represent an appropriate first-line option in selected patients with a PD-L1 TPS ≥ 90%. Larger prospective studies are warranted to refine treatment selection in this setting.


  • Clinical Features and Survival Outcomes in Primary Intestinal Lymphoma: A Multicenter Retrospective Study

    by Merve Turan, Nuriye Özdemir, Mehmet KüçÜkÖner, Asude Aksoy, Hilmi Kodaz, Mesut Şeker

    Ejmi Eurasian Journal of Medical Investigation

  • Open Access

    The Prognostic Role of Systemic Inflammatory Markers Before Abiraterone/Enzalutamide Therapy in Metastatic Castration-Resistant Prostate Cancer

    by Harun Muğlu, Erdem Sünger, Lamia Şeker Can, Jamshid Hamdard, Özgür Açıkgöz, Özcan Yıldız, Ömer Fatih Ölmez, Mesut Şeker, Ahmet Bilici

    Objective: To investigate the prognostic value of systemic inflammatory markers (SIM)—namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ra-tio (PLR)—on survival outcomes and treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone (ABI) or enzalu-tamide (ENZA) therapy. Methods: This two-center retrospective observational study analyzed clinical data of 106 patients diagnosed with mCRPC. The cut-off values for NLR and PLR were deter-mined as 2.83 and 156, respectively. Their effects on progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. Changes in SIM before and after ABI/ENZA treatment were assessed using the Wilcoxon signed-rank test. Results: Lower NLR (≤2.83) and PLR (≤156) levels were significantly associated with longer PFS and OS. In multivariate analysis, only high PLR emerged as an independent adverse prognostic factor for OS (HR: 2.01; p=0.026). Treatment response was an inde-pendent predictor of PFS. No significant changes were observed in MPV, PDW, or P-LCR levels after treatment. Conclusion: SIM such as NLR and especially PLR may serve as practical and accessible tools for predicting survival in mCRPC patients. However, further prospective studies are warranted.

  • Open Access

    Factors Affecting the Survival of Metastatic Breast Cancer Patients Treated with CDK 4/6 Inhibitors

    by Zehra Sucuoğlu İşleyen, Harun Muğlu, Zeynep Alaca Topçu, Mehmet Beşiroğlu, Ayşe İrem Yasin, Atakan Topçu, Melih Şimşek, Mesut Şeker, Hacı Mehmet Türk

    Background and Objective: We aim to determine the efficacy and the factors associated with the effectiveness of first-line CDK4/6i (ribociclib or palbociclib) treatment in HR-positive, HER2-negative MBC patients. Materials and Methods: This is a retrospective, cross-sectional, and descriptive study. Ninety patients with metastatic breast cancer receiving CDK 4/6i treatment from three different oncology clinics were included in this study. Results: Of the patients, 56 (62.2%) received ribociclib, and 34 (37.8%) were administered palbociclib. There was no significant difference between the groups regarding age, gender, comorbidities, ECOG performance status, or menopausal status (p > 0.05). The cut-off values for ER, PR, and Ki-67 levels were determined via ROC curve analysis. These values were found to be 80% for ER levels, 50% for PR levels, and 30% for Ki-67 levels. PFS was significantly longer for patients with ER levels greater than 80% and Ki-67 expression levels less than 30% according to multivariate analysis. Among the patients included in our study, the median PFS was 22.41 months for the patients with Ki-67 levels of 30% and above, while the median PFS was 17.24 months for the patients with ER levels of 80% and below. Among the patients with a combined ER of 80% or less and a Ki-67 of 30% or more, the median PFS was 12.42 months (p < 0.001). Conclusions: This study demonstrates that CDK4/6i therapies led to longer PFS among patients with ER levels greater than 80% and Ki-67 expression levels less than 30%. It is essential to determine which patient group benefits more from first-line CDK4/6is therapy.


  • Open Access

    Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram

    by Ayse Irem Yasin, Mahmut Uluganyan, Zehra Sucuoglu Isleyen, Atakan Topcu, Abdallah Tm Shbair, Melih Simsek, Mehmet Besiroglu, Yeliz Emine Ersoy, Hacı Mehmet Türk, Mesut Seker

    Objective: We aimed to evaluate cardiac safety profile of ribociclib with 24-h rhythm Holter ECG. Material and method: Forty-two female metastatic breast cancer patients were included in the study. Rhythm Holter ECG was performed before starting treatment with ribociclib and after 3 months of the treatment initiation. Results: The mean age of the patients was 56.36 ± 12.73. 52.4% (n = 22) of the patients were using ribociclib in combination with fulvestrant and 47.6% (n = 20) with aromatase inhibitors. None of the patients developed cardiotoxicity. When the rhythm Holter results before and in third month of the treatment were compared, there was no statistically significant difference. Conclusion: This is the first study evaluating effects of ribociclib treatment on cardiac rhythm with Holter ECG. The findings suggested ribociclib has a low risk of causing early cardiotoxicity.


  • Open Access

    Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

    by Sabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, Ayberk Bayramgil, Fahri Akgul, Seda Kahraman, Musa Baris Aykan, Yunus Emre Altıntas, Kaan Helvaci, Yuksel Urun, et al.

    Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess the optimal dosing regimen in a real-life setting. We retrospectively analysed 263 patients with mCRC from multiple medical oncology clinics in Turkey. Treatment responses and prognostic factors for survival were evaluated using univariate and multivariate analysis. Of the patients, 120 were male, and 143 were female; 28.9% of tumors were located in the rectum. RAS mutations were present in 3.0% of tumors, while BRAF, K-RAS, and N-RAS mutations were found in 3.0%, 29.7%, and 25.9% of tumor tissues, respectively. Dose escalation was preferred in 105 (39.9%) patients. The median treatment duration was 3.0 months, with an objective response rate (ORR) of 4.9%. Grade ≥ 3 treatment-related toxicity occurred in 133 patients, leading to discontinuation, interruption, and modification rates of 50.6%, 43.7%, and 79.0%, respectively. Median progression-free survival (PFS) and overall survival (OS) were 3.0 and 8.1 months, respectively. RAS/RAF mutation (hazard ratio [HR] 1.5, 95% confidence interval [CI] 1.1-2.3; P = 0.01), pretreatment carcinoembryonic antigen (CEA) levels (HR 1.6, 95% CI 1.1-2.3; P = 0.008), and toxicity-related treatment interruption or dose adjustment (HR 1.6, 95% CI 1.1-2.4; P = 0.01) were identified as independent prognostic factors for PFS. Dose escalation had no significant effect on PFS but was associated with improved OS (P < 0.001). Independent prognostic factors for OS were the initial TNM stage (HR 1.3, 95% CI 1.0-1.9; P = 0.04) and dose interruption/adjustment (HR 0.4, 95% CI 0.2-0.9; P = 0.03). Our findings demonstrate the efficacy and safety of regorafenib. Treatment line influences the response, with dose escalation being more favorable than adjustment or interruption, thus impacting survival.


  • Differentiation of lung and breast cancer brain metastases: Comparison of texture analysis and deep convolutional neural networks

    by Mehmet Ali Gultekin, Abdusselim Adil Peker, Ayse Betul Oktay, Haci Mehmet Turk, Dilek Hacer Cesme, Abdallah T. M. Shbair, Temel Fatih Yilmaz, Ahmet Kaya, Ayse Irem Yasin, Mesut Seker, et al.

    Purpose: Metastases are the most common neoplasm in the adult brain. In order to initiate the treatment, an extensive diagnostic workup is usually required. Radiomics is a discipline aimed at transforming visual data in radiological images into reliable diagnostic information. We aimed to examine the capability of deep learning methods to classify the origin of metastatic lesions in brain MRIs and compare the deep Convolutional Neural Network (CNN) methods with image texture based features.Methods: One hundred forty three patients with 157 metastatic brain tumors were included in the study. The statistical and texture based image features were extracted from metastatic tumors after manual segmentation process. Three powerful pre‐trained CNN architectures and the texture‐based features on both 2D and 3D tumor images were used to differentiate lung and breast metastases. Ten‐fold cross‐validation was used for evaluation. Accuracy, precision, recall, and area under curve (AUC) metrics were calculated to analyze the diagnostic performance.Results: The texture‐based image features on 3D volumes achieved better discrimination results than 2D image features. The overall performance of CNN architectures with 3D inputs was higher than the texture‐based features. Xception architecture, with 3D volumes as input, yielded the highest accuracy (0.85) while the AUC value was 0.84. The AUC values of VGG19 and the InceptionV3 architectures were 0.82 and 0.81, respectively.Conclusion: CNNs achieved superior diagnostic performance in differentiating brain metastases from lung and breast malignancies than texture‐based image features. Differentiation using 3D volumes as input exhibited a higher success rate than 2D sagittal images.